You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 11, 2024

~ Buy the LORBRENA (lorlatinib) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR LORBRENA


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Lorbrena

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03737994 ↗ Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer Active, not recruiting NRG Oncology Phase 2 2019-04-01 This National Cancer Institute (NCI)-NRG ALK Protocol phase II trial studies how well a combination of different biomarker/ALK inhibitors work in treating patients with stage IV ALK positive non-squamous non-small cell lung cancer. Lorlatinib, ceritinib, alectinib, brigatinib, ensartinib, and crizotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as pemetrexed, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether a combination of biomarker/ALK inhibitors or chemotherapy may work better in treating patients with ALK positive non-squamous non-small cell lung cancer.
NCT03737994 ↗ Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer Active, not recruiting National Cancer Institute (NCI) Phase 2 2019-04-01 This National Cancer Institute (NCI)-NRG ALK Protocol phase II trial studies how well a combination of different biomarker/ALK inhibitors work in treating patients with stage IV ALK positive non-squamous non-small cell lung cancer. Lorlatinib, ceritinib, alectinib, brigatinib, ensartinib, and crizotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as pemetrexed, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether a combination of biomarker/ALK inhibitors or chemotherapy may work better in treating patients with ALK positive non-squamous non-small cell lung cancer.
NCT03878524 ↗ Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Recruiting Oregon Health and Science University Phase 1 2020-04-01 This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has. This study is also being done to understand why cancer drugs can stop working and how different cancers in different people respond to different types of therapy.
NCT03878524 ↗ Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Recruiting Prospect Creek Foundation Phase 1 2020-04-01 This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has. This study is also being done to understand why cancer drugs can stop working and how different cancers in different people respond to different types of therapy.
NCT03878524 ↗ Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Recruiting OHSU Knight Cancer Institute Phase 1 2020-04-01 This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has. This study is also being done to understand why cancer drugs can stop working and how different cancers in different people respond to different types of therapy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lorbrena

Condition Name

Condition Name for Lorbrena
Intervention Trials
Lung Cancer 2
Locally Advanced Pancreatic Adenocarcinoma 1
Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive 1
ALK Gene Rearrangement 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Lorbrena
Intervention Trials
Lung Neoplasms 4
Carcinoma, Non-Small-Cell Lung 3
Lymphoma 2
Leukemia, Myeloid, Chronic-Phase 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lorbrena

Trials by Country

Trials by Country for Lorbrena
Location Trials
United States 45
China 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Lorbrena
Location Trials
Colorado 2
Virginia 2
Texas 2
Tennessee 2
Oregon 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lorbrena

Clinical Trial Phase

Clinical Trial Phase for Lorbrena
Clinical Trial Phase Trials
Phase 2 3
Phase 1/Phase 2 1
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Lorbrena
Clinical Trial Phase Trials
Recruiting 3
Active, not recruiting 1
Not yet recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lorbrena

Sponsor Name

Sponsor Name for Lorbrena
Sponsor Trials
Pfizer 3
Massachusetts General Hospital 1
SCRI Development Innovations, LLC 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Lorbrena
Sponsor Trials
Other 7
Industry 4
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.